% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@MISC{Galldiks:908214,
author = {Galldiks, Norbert and Werner, Jan-Michael and Stoffels,
Gabriele and Kocher, Martin and Tscherpel, Caroline and
Jain, Rajan and Shah, Nadim and Fink, Gereon and Langen,
Karl-Josef and Lohmann, Philipp},
title = {{NIMG}-05. {THE} {T}2-{FLAIR} {MISMATCH} {SIGN} {IN}
{IDH}-{MUTANT} {ASTROCYTOMAS} - {IS} {THERE} {AN}
{ASSOCIATION} {WITH} {FET} {PET} {UPTAKE}?},
reportid = {FZJ-2022-02465},
year = {2019},
abstract = {BACKGROUNDThe purpose of this study was (i) to assess the
reproducibility of the previously described T2-FLAIR
mismatch sign as a highly specific MR imaging marker in
non-enhancing IDH-mutant, 1p/19q non-codeleted lower-grade
gliomas (LGG) of the WHO grades II or III, and (ii) its
association with the uptake of the radiolabeled amino acid
O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) in PET to further
metabolically characterize that sign, which is currently
poorly understood.METHODSConsecutive MRI and dynamic FET PET
scans (n=134) from newly diagnosed and neuropathologically
confirmed IDH-mutant LGG (n=65) and IDH-wildtype gliomas as
control group (n=69) were evaluated by two independent
raters to assess presence/absence of the T2-FLAIR mismatch
sign as well as FET uptake. Interrater agreement was
assessed using Cohen’s kappa (κ), as well as diagnostic
performance (i.e., positive/negative predictive value; PPV,
NPV) of the T2-FLAIR mismatch sign to identify IDH-mutant
astrocytomas.RESULTSIn the LGG group, 13 patients $(20\%)$
had a T2-FLAIR mismatch sign, which could be identified with
a substantial interrater agreement (κ=0.75). In contrast,
that sign was absent in IDH-wildtype gliomas. All 13 cases
that were positive for the T2/FLAIR mismatch sign were
IDH-mutant, 1p/19q non-codeleted tumors $(PPV=100\%,$
$NPV=57\%).$ Interestingly, compared to IDH-mutant gliomas
without the T2-FLAIR mismatch sign, the sign was
significantly (P=0.027; 10 of 13 patients) associated with a
negative FET PET scan (i.e., 5 tumors with indifferent FET
uptake comparable to the background activity, or FET uptake
below background activity (photopenic defect) in 5
tumors).CONCLUSIONSWith a robust interrater agreement, our
findings are in line with previously reported findings
regarding the T2-FLAIR mismatch sign. Additionally, the
T2-FLAIR mismatch sign seems to be significantly related
with a lack of increased FET uptake in PET, which may help
to further characterize patients with that sign.
Notwithstanding, the clinical relevance of this imaging
constellation warrants further investigation.},
cin = {INM-11 / INM-4 / JARA-BRAIN / INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-11-20170113 / I:(DE-Juel1)INM-4-20090406 /
I:(DE-Juel1)VDB1046 / I:(DE-Juel1)INM-3-20090406},
pnm = {5253 - Neuroimaging (POF4-525)},
pid = {G:(DE-HGF)POF4-5253},
typ = {PUB:(DE-HGF)4},
url = {https://juser.fz-juelich.de/record/908214},
}